De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies

Donor‐specific antibodies (DSAs) are associated with an increased risk of antibody‐mediated rejection and graft failure. In BENEFIT and BENEFIT‐EXT, kidney‐transplant recipients were randomized to receive belatacept more intense (MI)–based, belatacept less intense (LI)–based, or cyclosporine‐based i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bray, R. A., Gebel, H. M., Townsend, R., Roberts, M. E., Polinsky, M., Yang, L., Meier‐Kriesche, H.‐U., Larsen, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055714/
https://www.ncbi.nlm.nih.gov/pubmed/29509295
http://dx.doi.org/10.1111/ajt.14721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055714/
https://www.ncbi.nlm.nih.gov/pubmed/29509295
http://dx.doi.org/10.1111/ajt.14721

Ejemplares similares